Comparative analysis of survivin expression in untreated and relapsed canine lymphoma

Journal of Veterinary Internal Medicine

Volumn 22, Issue 4, 2008, Pages 989-995

  Rebhun, R B ^a   Lana, S E ^a   Ehrhart, E J ^a   Charles, J B ^a   Thamm, D H ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

Author keywords

Apoptosis; Dogs; IAP; Lymphosarcoma; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CHOP PROTOCOL; CYCLOPHOSPHAMIDE; DOXORUBICIN; MICROTUBULE ASSOCIATED PROTEIN; PREDNISONE; TUMOR PROTEIN; VINCRISTINE;

ANIMAL; ANIMAL DISEASE; ARTICLE; COMPARATIVE STUDY; DOG; DOG DISEASE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LYMPHOMA; MALE; METABOLISM; RECURRENT DISEASE; TIME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOG DISEASES; DOGS; DOXORUBICIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; LYMPHOMA; MALE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PREDNISONE; RECURRENCE; TIME FACTORS; VINCRISTINE;

ANIMALIA; CANIS FAMILIARIS; IVA;

EID: 47849118398     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2008.0143.x     Document Type: Article

References (28)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004;4:592-603.
3. Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 2004;5:897-907.
4. Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell 2002;9:459-470.
5. Cory S, Adams JM. The Bcl2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer 2002;2:647-656.
6. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580-584.
7. Altieri DC, Marchisio PC. Survivin apoptosis: An interloper between cell death and cell proliferation in cancer. Lab Invest 1999;79:1327-1333.
8. Adida C, Crotty PL, McGrath J, et al. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 1998;152:43-49.
9. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-921.
10. Velculescu VE, Madden SL, Zhang L, et al. Analysis of human transcriptomes. Nat Genet 1999;23:387-388.
11. Johnson ME, Howerth EW. Survivin: A bifunctional inhibitor of apoptosis protein. Vet Pathol 2004;41:599-607.
12. Adida C, Haioun C, Gaulard P, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000;96:1921-1925.
13. Schielte EJ, Medeiros LJ, Goy A, et al. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol 2004;22:1682-1688.
14. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
15. Withrow SJ, Vail DM. Withrow and MacEwen's Small Animal Clinical Oncology, 4th ed. Edinburgh, Scotland: Elsevier Saunders; 2007.
16. Theilen GH, Madewell BR. Veterinary Cancer Medicine, 2nd ed. Philadelphia, PA: Lea & Febiger; 1987.
17. Greenlee PG, Filippa DA, Quimby FW, et al. Lymphomas in dogs. A morphologic, immunologic, and clinical study. Cancer 1990;66:480-490.
18. Teske E, van Heerde P, Rutteman GR, et al. Prognostic factors for treatment of malignant lymphoma in dogs. J Am Vet Med Assoc 1994;205:1722-1728.
19. Teicher BA, Andrews PA. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, 2nd ed. Totowa, NJ: Humana Press; 2004.
20. Scase TJ, Edwards D, Miller J, et al. Canine mast cell tumors: Correlation of apoptosis and proliferation markers with prognosis. J Vet Intern Med 2006;20:151-158.
21. Zhu N, Gu L, Findley HW, et al. An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. Oncogene 2004;23:7545-7551.
22. Burnett RC, Vernau W, Modiano JF, et al. Diagnosis of canine lymphoid neoplasia using clonal rearrangements of antigen receptor genes. Vet Pathol 2003;40:32-41.
23. Rosales C, Jeglum KA, Obrocka M, et al. Cytolytic activity of murine anti-dog lymphoma monoclonal antibodies with canine effector cells and complement. Cell Immunol 1988;115:420-428.
24. Steplewski Z, Resales C, Jeglum KA, et al. In vivo destruction of canine lymphoma mediated by murine monoclonal antibodies. In Vivo 1990;4:231-234.
25. Suter SE, Chein MB, von Messling V, et al. In vitro canine distemper virus infection of canine lymphoid cells: A prelude to oncolytic therapy for lymphoma. Clin Cancer Res 2005;11:1579-1587.
26. Kisseberth WC, Nadella MV, Breen M, et al. A novel canine lymphoma cell line: A translational and comparative model for lymphoma research. Leuk Res 2007;31:1709-1720.
27. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
28. Mullins MN, Lana SE, Dernell WS, et al. Cyclooxygenase-2 expression in canine appendicular osteosarcomas. J Vet Intern Med 2004;18:859-865.